Senate Hearing To Examine High Insulin Prices and Legislation Aiming for Major Price Reductions

Bipartisan Senate legislation introduced to cap the price of insulin at $35 per month for people with private insurance
Senate HELP Committee will hold a hearing on May 10 about the cost of insulin
Top executives of Eli Lilly, Novo Nordisk, and Sanofi will testify before the Senate Health Committee on May 10 to discuss lowering prices of their diabetes drugs.
The hearing will also feature executives from major pharmacy benefit managers (PBMs)
Senate proposals aimed at lowering the cost of insulin include capping list price at $20 per vial or $35 per month for people with private insurance